996 related articles for article (PubMed ID: 24120657)
1. Can nanomedicines kill cancer stem cells?
Zhao Y; Alakhova DY; Kabanov AV
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1763-83. PubMed ID: 24120657
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine-mediated cancer stem cell therapy.
Shen S; Xia JX; Wang J
Biomaterials; 2016 Jan; 74():1-18. PubMed ID: 26433488
[TBL] [Abstract][Full Text] [Related]
3. Eradicating the tumor "seeds": nanomedicines-based therapies against cancer stem cells.
Li L; Ni R; Zheng D; Chen L
Daru; 2023 Jun; 31(1):83-94. PubMed ID: 36971921
[TBL] [Abstract][Full Text] [Related]
4. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
5. Delivering cancer stem cell therapies - a role for nanomedicines?
Schätzlein AG
Eur J Cancer; 2006 Jun; 42(9):1309-15. PubMed ID: 16682183
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming Cancer Stem-like Cells with Nanoforskolin Enhances the Efficacy of Paclitaxel in Targeting Breast Cancer.
Singh D; Singh P; Pradhan A; Srivastava R; Sahoo SK
ACS Appl Bio Mater; 2021 Apr; 4(4):3670-3685. PubMed ID: 35014452
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cells and drug resistance: the potential of nanomedicine.
Vinogradov S; Wei X
Nanomedicine (Lond); 2012 Apr; 7(4):597-615. PubMed ID: 22471722
[TBL] [Abstract][Full Text] [Related]
9. Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach.
Malhi S; Gu X
Expert Opin Drug Deliv; 2015 Jul; 12(7):1177-201. PubMed ID: 25601619
[TBL] [Abstract][Full Text] [Related]
10. Cancer stem cell theory: therapeutic implications for nanomedicine.
Wang K; Wu X; Wang J; Huang J
Int J Nanomedicine; 2013; 8():899-908. PubMed ID: 23467584
[TBL] [Abstract][Full Text] [Related]
11. Nanomaterials for targeted drug delivery to cancer stem cells.
Orza A; Casciano D; Biris A
Drug Metab Rev; 2014 May; 46(2):191-206. PubMed ID: 24697156
[TBL] [Abstract][Full Text] [Related]
12. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
13. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
14. Approaches to Targeting Cancer Stem Cells in Solid Tumors.
Caldas-Lopes E; Gomez-Arteaga A; Guzman ML
Curr Stem Cell Res Ther; 2019; 14(5):421-427. PubMed ID: 30806324
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem cells, metabolism, and therapeutic significance.
Yang M; Liu P; Huang P
Tumour Biol; 2016 May; 37(5):5735-42. PubMed ID: 26864589
[TBL] [Abstract][Full Text] [Related]
16. EpCAM-Antibody-Labeled Noncytotoxic Polymer Vesicles for Cancer Stem Cells-Targeted Delivery of Anticancer Drug and siRNA.
Chen J; Liu Q; Xiao J; Du J
Biomacromolecules; 2015 Jun; 16(6):1695-705. PubMed ID: 25988863
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic approaches targeting cancer stem cells.
Pan Y; Ma S; Cao K; Zhou S; Zhao A; Li M; Qian F; Zhu C
J Cancer Res Ther; 2018; 14(7):1469-1475. PubMed ID: 30589025
[TBL] [Abstract][Full Text] [Related]
18. Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
Zhou J; Sun M; Jin S; Fan L; Zhu W; Sui X; Cao L; Yang C; Han C
Drug Deliv; 2019 Dec; 26(1):281-289. PubMed ID: 30880491
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cells: a potential target for cancer therapy.
Qiu H; Fang X; Luo Q; Ouyang G
Cell Mol Life Sci; 2015 Sep; 72(18):3411-24. PubMed ID: 25967289
[TBL] [Abstract][Full Text] [Related]
20. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
Mitra A; Mishra L; Li S
Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
